Although the FDA's 27 new approvals are down from the 15-year high of 2012, the newcomers pack powerful commercial potential.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Molecular and Cellular Biochemistry Open Access 27 October 2022
-
ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database
Journal of Cheminformatics Open Access 26 June 2018
-
Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward
Blood Cancer Journal Open Access 04 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
07 February 2014
The titles of David Greber and Ulrik Schulze have been updated online.
Rights and permissions
About this article
Cite this article
Mullard, A. 2013 FDA drug approvals. Nat Rev Drug Discov 13, 85–89 (2014). https://doi.org/10.1038/nrd4239
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4239
This article is cited by
-
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
Molecular and Cellular Biochemistry (2023)
-
Drug repurposing for antimicrobial discovery
Nature Microbiology (2019)
-
ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database
Journal of Cheminformatics (2018)
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)
-
Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward
Blood Cancer Journal (2016)